卢塞恩工具箱3:数字健康与人工智能优化早期乳腺癌诊疗路径的多学科共识
卢塞恩工具箱3倡议针对早期乳腺癌诊疗中数字健康与人工智能整合的证据需求,通过改良德尔菲共识流程,由来自27个国家、16个医学协会/试验组/患者组织的112名成员参与,识别并优先排序了15个关键医学知识缺口,并开发了13项PICO格式试验设计,98%的陈述达成共识或多数投票。推荐强调精准医学、以患者为中心的照护及跨学科协作,以改善乳腺癌诊疗的结局、效率与公平性。
要点
- 识别了早期乳腺癌诊疗全程15个数字健康与AI相关关键知识缺口。
- 开发13项PICO格式试验设计,98%陈述达成共识或多数投票。
- 推荐聚焦精准医学、患者中心照护和跨学科协作。
核心结论
- 卢塞恩工具箱3为早期乳腺癌数字健康与AI整合提供了可操作的试验路线图。
研究设计与样本
- 采用改良德尔菲共识流程,112名来自27个国家、16个医学协会/试验组/患者组织的成员参与。
主要发现
- 识别并优先排序了从诊断到治疗及生存期的15个关键医学知识缺口。
- 针对缺口开发了13项PICO格式试验设计,98%的陈述达成共识或多数投票。
关键数值与推荐
- 知识缺口包括基于AI的乳腺X线筛查、个性化筛查策略、数字知识数据库、AI驱动的治疗优化及数字化监测与支持治疗。
临床怎么用
- 推荐将精准医学、以患者为中心的照护和跨学科协作融入早期乳腺癌数字健康与AI的临床研究与实践中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Lucerne Toolbox 3 initiative addresses the pressing need for evidence-based integration of digital health and artificial intelligence (AI) technologies in early breast cancer care. The multidisciplinary consortium identified and prioritised 15 crucial medical knowledge gaps across the patient journey, from diagnosis to treatment and survivorship, using a modified Delphi consensus process with 112 unique members from 27 countries and 16 medical societies, trial groups, and patient organisations. The knowledge gaps include AI-based mammography screening, personalised screening strategies, digital knowledge databases, AI-driven treatment optimisation, and digitally delivered monitoring and supportive care. The consortium developed 13 trial designs in the Population, Intervention, Comparison, and Outcome format to address these gaps, achieving consensus or majority vote in 98% of statements. The recommendations emphasise precision medicine, patient-centred care, and interdisciplinary collaboration to improve outcomes, efficiency, and equity in breast cancer care. By presenting a roadmap for actionable trials, Lucerne Toolbox 3 sets a foundation for advancing digital health in breast cancer care.
引用
- Pfob A, Pinker K, Vaz-Luis I, et al. The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensus. Lancet Oncol. 2025. PMID: 41308690. doi:10.1016/S1470-2045(25)00463-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。